Biocon announced that the Health Products Regulatory Authority (HPRA), Ireland, conducted a GMP inspection of one of Biocon Biologics' new monoclonal antibody drug substance manufacturing facilities in Biocon Park, Bengaluru, India, between 28 March and 01 April 2022.
The inspection report contains no 'critical' observations and only one of the deficiencies is categorized as 'major' which is being addressed expeditiously in consultation with the regulatory agency
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
